2017
DOI: 10.1093/annonc/mdx393.139
|View full text |Cite
|
Sign up to set email alerts
|

Phase II study of Ccr-based dose-control of S-1 in the first-line chemotherapy of S-1/oxaliplatin (SOX) + bevacizumab regimen for advanced colorectal cancer

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles